Global generic and off-patent branded-drug maker formed from the merger of Mylan and Pfizer's Upjohn unit.
Global generic and off-patent branded-drug maker formed from the merger of Mylan and Pfizer's Upjohn unit.
Earns from large volumes of lower-priced copies of off-patent drugs and from older brands such as Lipitor and Viagra, sold through wholesalers and pharmacies in many countries, with much of the business outside the US. Since 2022 it has sold several units, including its biosimilars unit to Biocon, to cut debt.
Moat: narrow (scale, distribution). Broad global manufacturing and distribution scale, but limited pricing power in commoditized generics.
Headquarters: Canonsburg, Pennsylvania, United States · Founded: 2020 · Employees: 30,000
Size Viatris (VTRS) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $23.3B, the 447th largest of 3,085 United States companies the cockpit tracks. Shares closed at $20.28 on 18 Nov 2026.
Performance Over six months the shares gained 23.1%, against +7.6% for the median peer and -2.2% for the United States market (cap-weighted) — 5th highest of 21 in its peer set.
Growth Revenue grew 4.8% over the last twelve months (peer median +29.3%); the operating margin is 10.8% (peer median 22.7%).
Valuation It trades at 7.5× forward earnings against a peer median of 22.4× (cheapest of 19).
Price implies For today's price to make sense, revenue must grow about 11% a year for seven years (Req g). Recent delivered growth is +4%, so the hurdle is +8 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 3.1 points below its cost of capital (8.0% WACC).
Credit Viatris has 5 bonds outstanding ($6.42B), rated BB+ by the agencies and trading like BBB- at a weighted spread of 133 bp.
Short interest Short interest is 3.1% of the free float (30 Oct 2026).
Next results Next results expected around 1 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $14.7B | $14.3B | $14.7B | $15.4B | $16.2B |
| Revenue growth | — | -3% | -4% | -5% | — |
| Gross profit | $6.01B | $5.65B | $6.22B | $6.57B | $6.69B |
| EBITDA | $4.40B | $3.89B | $4.57B | $4.73B | $5.36B |
| Net income | -$608M | -$3.51B | -$634M | $54.7M | $2.08B |
| Free cash flow | $2.11B | $1.94B | $1.98B | $2.42B | $2.55B |
| Capital expenditure | $514M | $465M | $359M | $474M | $443M |
| Total debt | $13.6B | $14.7B | $14.3B | $18.4B | $19.5B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Viatris VTRS | $23.3B | +23% | +5% | 11% | 7.5× | 11.2% |
| Teva Pharmaceutical Industries Limited Sponsored ADR TEVA | $49.3B | +23% | -4% | 19% | 15.0× | 10.5% |
| Sandoz SDZ.SW | $41.7B | +26% | +1% | 15% | 24.5× | 7.5% |
| Dr. Reddy's Laboratories DRREDDY.NS | $12.5B | +5% | -4% | 9% | 32.0× | 30.7% |
| Hikma Pharmaceuticals HIK.L | $4.58B | +15% | +2% | 20% | 9.8× | 2.0% |
| Amneal Pharmaceuticals AMRX | $7.62B | +79% | +9% | 16% | 19.2× | 17.2% |
| Lupin LUPIN.NS | $9.67B | -14% | +24% | 24% | 21.0× | 8.8% |
| Aurobindo Pharma AUROPHARMA.NS | $11.0B | +19% | +14% | 15% | 22.3× | 21.1% |
| Cipla CIPLA.NS | $12.2B | +1% | -1% | 13% | 29.1× | 28.4% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | VTRS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +8.7% | +6.1% | 8th highest of 21 |
| 6-month return | +23.1% | +7.6% | 5th highest of 21 |
| Distance from 52-week high | -4.3% | -10.3% | 5th highest of 21 |
| Revenue growth (TTM) | +4.8% | +29.3% | 2nd lowest of 21 |
| Operating margin | 10.8% | 22.7% | 4th lowest of 21 |
| Forward P/E | 7.5× | 22.4× | cheapest of 19 |
| Growth the price implies (Req g, 7 yrs) | 11.2% | 4.1% | 8th most demanding of 19 |
| Growth delivered (Del g) | +3.7% | +12.8% | lowest of 19 |
| Hurdle (Req g minus delivered) | +7.5 pp | -13.0 pp | 3rd most demanding of 19 |
| ROIC minus cost of capital | -3.1 pp | +9.7 pp | 3rd lowest of 21 |
| EV / EBITDA | 7.9× | 18.8× | 2nd cheapest of 18 |
| Net debt / EBITDA | 2.7× | -0.5× | most indebted of 18 |
| Bond spread | 133 bp | n/a | — |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Viatris VTRS | United States | $23.3B | +23% | +5% | 11% | 7.5× | 11.2% | +3.7% |
| Incyte INCY | United States | $24.0B | +21% | +25% | 12% | 15.1× | 14.2% | +14.0% |
| Sigma Healthcare SIG.AX | Australia | $22.4B | +2% | +209% | 9% | 38.4× | 28.9% | +26.1% |
| Hansoh Pharma 3692.HK | Hong Kong | $25.3B | -3% | +25% | 38% | 25.8× | 7.9% | +10.8% |
| Insmed INSM | United States | $26.3B | +3% | +240% | -42% | n/a | n/a | n/a |
| Alnylam Pharmaceuticals ALNY | United States | $20.0B | -50% | +56% | 20% | 21.2× | 0.5% | +49.8% |
| Roivant Sciences ROIV | United States | $28.1B | +20% | +102% | -3,234% | n/a | n/a | n/a |
| Innovent Biologics 1801.HK | Hong Kong | $18.9B | +4% | +43% | 17% | 52.3× | 11.6% | +26.8% |
| Torrent Pharmaceuticals TORNTPHARM.NS | India | $18.8B | +3% | +42% | 22% | 70.2× | 37.6% | +11.3% |
| Shionogi & 4507.T | Japan | $17.6B | +3% | +46% | 29% | 11.8× | 0.2% | +11.0% |
| Divi's Laboratories DIVISLAB.NS | India | $31.3B | +60% | +22% | 34% | 73.5× | 47.1% | +8.9% |
| Daiichi Sankyo 4568.T | Japan | $31.4B | +8% | +17% | 13% | 18.4× | 7.6% | +17.1% |
| Astellas Pharma 4503.T | Japan | $31.4B | +17% | +19% | 23% | 12.9× | -9.0% | +11.4% |
| Ascendis Pharma A/S ASND | United States | $16.9B | +12% | +94% | 18% | 28.0× | 19.2% | +152.4% |
| Exelixis EXEL | United States | $16.7B | +37% | +9% | 40% | 17.7× | -3.8% | +18.6% |
| Swedish Orphan Biovitrum SOBI.ST | Sweden | $16.1B | +6% | +15% | 30% | 24.1× | -2.1% | +13.1% |
| Jazz Pharmaceuticals Public JAZZ | United States | $15.9B | +4% | +13% | 25% | 9.3× | -2.8% | +12.5% |
| Orion ORNAV.HE | Finland | $15.7B | +41% | +34% | 38% | 23.6× | -6.2% | +11.7% |
| Zoetis ZTS | United States | $34.8B | +7% | +1% | 37% | 13.8× | -2.9% | +7.2% |
| PharmaEssentia 6446.TW | Taiwan | $15.0B | +67% | +78% | 40% | 31.9× | 23.7% | +94.8% |
| Yunnan Baiyao 000538.SZ | China | $15.0B | +11% | +5% | 11% | 18.3× | -0.2% | +4.7% |
Viatris has 5 bonds outstanding with $6.42B face value. The agencies rate it BB+; its bonds trade like BBB-. Weighted yield 6.12%, a spread of 133 bp over government bonds.